BMC Cancer

Table 3 Hazard ratios for metastasis and death by medication use and interaction with tumor PIK3CA mutation among women with metastatic breast cancer (N = 267)

From: Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer

	N	%	Multivariate ^a
	N	%	HR	95% CI	p-value	p-interaction^b
Metastasis
Aspirin	54	20.2	0.91	0.64–1.27	0.592	0.006
NSAIDs	85	31.8	0.86	0.65–1.14	0.293	0.516
Aspirin/NSAIDs	108	40.4	0.84	0.63–1.10	0.193	0.182
Statins	34	12.7	0.79	0.54–1.17	0.241	0.994
Beta Blockers	26	9.7	0.89	0.57–1.37	0.594	0.732
Survival
Aspirin	54	20.2	1.04	0.68–1.54	0.855	0.026
NSAIDs	85	31.8	0.90	0.63–1.27	0.535	0.793
Aspirin/NSAIDs	108	40.4	0.90	0.64–1.25	0.525	0.131
Statins	34	12.7	0.99	0.63–1.57	0.980	0.570
Beta Blockers	26	9.7	1.25	0.76–2.04	0.385	0.544

^aModels adjusted for age, stage, PR status, grade, chemotherapy use for primary diagnosis, PIK3CA mutation status
^bp for interaction between medication use and PIK3CA mutation status

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com